BlackRock Fund Advisors recently announced the acquisition of new stake in Uxin Limited (NASDAQ:UXIN). This fresh investment now brings its stake to 0.60% valued currently at $2.15 million. In addition, Renaissance Technologies LLC raised its holdings by 0.45 million to 1.0 million shares.

With over 3.22 million Uxin Limited (UXIN) shares trading Friday and a closing price of $0.91 on the day, the dollar volume was approximately $2.93 million. The shares have shown a negative weekly performance of -21.55% and its price on 08/28/20 lost nearly -13.33%. Currently, there are 296.15M common shares owned by the public and among those 223.18M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for UXIN have a consensus price objective of $32.14. The analysts have set the share’s price value over the next 12 months at a high of $32.14 and a low of $32.14 should the stock experience a downside. Incidentally, analysts’ outlook for the Uxin Limited stock is 2.70 for the next 12 months. But an upside of 97.17% will see the stock hit the forecast high price target while mean target price for the stock is $32.14.

The top 3 mutual fund holders in Uxin Limited are Wells Fargo Emerging Markets Equi, Baillie Gifford Overseas Growth F, and iShares Core MSCI Emerging Market. Wells Fargo Emerging Markets Equi owns 3.95 million shares of the company’s stock, all valued at over $5.02 million. iShares Core MSCI Emerging Market bought 10181.0 shares to bring its total holdings to over 0.93 million shares at a value of $1.18 million. iShares Core MSCI Emerging Market now owns shares totaling to 0.33% of the shares outstanding.

Shares of Uxin Limited (NASDAQ: UXIN) opened at $1.03, down -$0.02 from a prior closing price of $1.05. However, the script later closed the day at $0.91, down -13.33%. The company’s stock has a 5-day price change of -21.55% and -38.93% over the past three months. UXIN shares are trading -59.73% year to date (YTD), with the 12-month market performance down to -65.40% lower. It has a 12-month low price of $1.02 and touched a high of $3.80 over the same period. Currently, 3.22 million shares have been traded, compared to an average intraday trading volume of 1.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.14%, -33.96%, and -50.14% respectively.

Institutional ownership of Uxin Limited (NASDAQ: UXIN) shares accounts for 24.20% of the company’s 296.15M shares outstanding. Mutual fund holders own 3.23%, while other institutional holders and individual stakeholders account for 4.64% and — respectively.

It has a market capitalization of $296.40M. The earnings-per-share (ttm) stands at -$1.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.47% over the week and 5.42% over the month.

Analysts forecast that Uxin Limited (UXIN) will achieve an EPS of -$0.09 for the current quarter, -$0.08 for the next quarter and $0 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.09 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.16 a year ago.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Uxin Limited (UXIN) as a “Moderate Buy” at a consensus score of 2.70. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the UXIN, a number of firms have released research notes about the stock. JP Morgan stated their Neutral rating for the stock in a research note on October 23, 2019, with the firm’s price target at. Credit Suisse coverage for the Uxin Limited (UXIN) stock in a research note released on March 12, 2019 offered a Outperform rating with a price target of $7.70. JP Morgan was of a view on January 10, 2019 that the stock is Overweight, while Goldman gave the stock Neutral rating on December 21, 2018, issuing a price target of. Goldman on their part issued Buy rating on August 16, 2018.